Concizumab

Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia B. It is an anti-tissue factor pathway inhibitor.

Concizumab was approved for medical use in Canada in March 2023.

Medical uses
Concizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Names
Concizumab is the international nonproprietary name.